Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 223

1.

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD.

N Engl J Med. 2018 Jul 12;379(2):150-161. doi: 10.1056/NEJMoa1716435. Epub 2018 Jun 26.

2.

Basic science in a department of surgery.

Bolognesi DP.

Ann Surg. 2003 Dec;238(6 Suppl):S33. No abstract available.

PMID:
14703742
3.

HIV fusion and its inhibition.

LaBranche CC, Galasso G, Moore JP, Bolognesi DP, Hirsch MS, Hammer SM.

Antiviral Res. 2001 May;50(2):95-115. Review. No abstract available.

PMID:
11369431
4.

Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41.

Chen CH, Greenberg ML, Bolognesi DP, Matthews TJ.

AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):2037-41.

PMID:
11153086
5.

Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection.

Markert ML, Hicks CB, Bartlett JA, Harmon JL, Hale LP, Greenberg ML, Ferrari G, Ottinger J, Boeck A, Kloster AL, McLaughlin TM, Bleich KB, Ungerleider RM, Lyerly HK, Wilkinson WE, Rousseau FS, Heath-Chiozzi ME, Leonard JM, Haase AT, Shaw GM, Bucy RP, Douek DC, Koup RA, Haynes BF, Bolognesi DP, Weinhold KJ.

AIDS Res Hum Retroviruses. 2000 Mar 20;16(5):403-13.

PMID:
10772526
6.

Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs.

Tyler DS, Stanley SD, Bartlett JA, Bolognesi DP, Weinhold KJ.

J Surg Res. 1998 Oct;79(2):115-20.

PMID:
9758725
7.

Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus.

Langlois AJ, Desrosiers RC, Lewis MG, KewalRamani VN, Littman DR, Zhou JY, Manson K, Wyand MS, Bolognesi DP, Montefiori DC.

J Virol. 1998 Aug;72(8):6950-5.

9.

Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage.

Montefiori DC, Collman RG, Fouts TR, Zhou JY, Bilska M, Hoxie JA, Moore JP, Bolognesi DP.

J Virol. 1998 Mar;72(3):1886-93.

10.

HIV vaccines. Viral envelope fails to deliver?

Bolognesi DP, Matthews TJ.

Nature. 1998 Feb 12;391(6668):638-9. No abstract available.

PMID:
9490406
11.

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.

Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, Zhou JT, Bolognesi DP, Fauci AS, Montefiori DC.

J Infect Dis. 1997 Oct;176(4):924-32.

PMID:
9333150
12.

HIV. A clever hijacker of the immune system.

Bolognesi DP.

Curr Opin Immunol. 1997 Aug;9(4):549-50. No abstract available.

PMID:
9287181
13.

Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers.

Ferrari G, Humphrey W, McElrath MJ, Excler JL, Duliege AM, Clements ML, Corey LC, Bolognesi DP, Weinhold KJ.

Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1396-401.

14.

Noncytolytic CD8 T cell-mediated suppression of HIV replication.

Greenberg ML, Lacey SF, Chen CH, Bolognesi DP, Weinhold KJ.

Springer Semin Immunopathol. 1997;18(3):355-69. Review. No abstract available.

PMID:
9089954
15.

Overview of HIV vaccine development.

Bolognesi DP.

Antibiot Chemother (1971). 1996;48:63-7. Review. No abstract available.

PMID:
8726507
16.

IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).

Ferrari G, King K, Rathbun K, Place CA, Packard MV, Bartlett JA, Bolognesi DP, Weinhold KJ.

Clin Exp Immunol. 1995 Aug;101(2):239-48.

17.

Immunodeficiency.

Bolognesi DP, Cooper MD.

Curr Opin Immunol. 1995 Aug;7(4):433-5. Review. No abstract available.

PMID:
7495504
18.
19.

Multiple CTL specificities against autologous HIV-1-infected BLCLs.

Ahearne PM, Morgan RA, Sebastian MW, Bolognesi DP, Weinhold KJ.

Cell Immunol. 1995 Mar;161(1):34-41.

PMID:
7867083
20.

Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.

Keefer MC, Graham BS, Belshe RB, Schwartz D, Corey L, Bolognesi DP, Stablein DM, Montefiori DC, McElrath MJ, Clements ML, et al.

AIDS Res Hum Retroviruses. 1994 Dec;10(12):1713-23.

PMID:
7888231
21.

NIH conference. HIV vaccine development: a progress report.

Hoth DF, Bolognesi DP, Corey L, Vermund SH.

Ann Intern Med. 1994 Oct 15;121(8):603-11. Review.

PMID:
8085693
22.

HIV infection in vaccinated volunteers.

Belshe RB, Bolognesi DP, Clements ML, Corey L, Dolin R, Mestecky J, Mulligan M, Stablein D, Wright P.

JAMA. 1994 Aug 10;272(6):431. No abstract available.

PMID:
8040971
23.

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.

Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, Matthews T, Weinhold K, Bolognesi DP, Sposto R, et al.

JAMA. 1994 Aug 10;272(6):475-80.

PMID:
7913731
24.

Immunodeficiency.

Cooper MD, Bolognesi DP.

Curr Opin Immunol. 1994 Aug;6(4):597-9. Review. No abstract available.

PMID:
7946048
25.

Structural rearrangements in the transmembrane glycoprotein after receptor binding.

Matthews TJ, Wild C, Chen CH, Bolognesi DP, Greenberg ML.

Immunol Rev. 1994 Aug;140:93-104. Review. No abstract available.

PMID:
7821930
26.

Comparison of anti-HIV-1 ADCC reactivities in infected humans and chimpanzees.

Ferrari G, Place CA, Ahearne PM, Nigida SM Jr, Arthur LO, Bolognesi DP, Weinhold KJ.

J Acquir Immune Defic Syndr. 1994 Apr;7(4):325-31.

PMID:
8133445
27.

Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.

Javaherian K, Langlois AJ, Montefiori DC, Kent KA, Ryan KA, Wyman PD, Stott J, Bolognesi DP, Murphey-Corb M, Larosa GJ.

J Virol. 1994 Apr;68(4):2624-31.

28.

CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism.

Chen CH, Weinhold KJ, Bartlett JA, Bolognesi DP, Greenberg ML.

AIDS Res Hum Retroviruses. 1993 Nov;9(11):1079-86.

PMID:
8312050
29.

Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.

Haynes BF, Torres JV, Langlois AJ, Bolognesi DP, Gardner MB, Palker TJ, Scearce RM, Jones DM, Moody MA, McDanal C, et al.

J Immunol. 1993 Aug 1;151(3):1646-53.

PMID:
8335949
30.

The immune response to HIV: implications for vaccine development.

Bolognesi DP.

Semin Immunol. 1993 Jun;5(3):203-14. Review.

PMID:
8347841
31.

AIDS. Where has HIV been hiding?

Temin HM, Bolognesi DP.

Nature. 1993 Mar 25;362(6418):292-3. No abstract available.

PMID:
8455713
32.

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP, et al.

J Infect Dis. 1993 Mar;167(3):533-7.

PMID:
8095059
33.

Human immunodeficiency virus vaccines.

Bolognesi DP.

Adv Virus Res. 1993;42:103-48. Review. No abstract available.

PMID:
8430519
34.

Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy.

Haynes BF, Yasutomi Y, Torres JV, Gardner MB, Langlios AJ, Bolognesi DP, Matthews TJ, Scearce RM, Jones DM, Moody MA, et al.

Trans Assoc Am Physicians. 1993;106:33-41. No abstract available.

PMID:
8036743
35.

Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus.

Langlois AJ, Weinhold KJ, Matthews TJ, Greenberg ML, Bolognesi DP.

AIDS Res Hum Retroviruses. 1992 Sep;8(9):1641-52.

PMID:
1457210
36.

Changes in bioactive lipids, alkylacylglycerol and ceramide, occur in HIV-infected cells.

Van Veldhoven PP, Matthews TJ, Bolognesi DP, Bell RM.

Biochem Biophys Res Commun. 1992 Aug 31;187(1):209-16.

PMID:
1520301
37.

Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells.

Lambert DM, Petteway SR Jr, McDanal CE, Hart TK, Leary JJ, Dreyer GB, Meek TD, Bugelski PJ, Bolognesi DP, Metcalf BW, et al.

Antimicrob Agents Chemother. 1992 May;36(5):982-8.

38.

The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.

Javaherian K, Langlois AJ, Schmidt S, Kaufmann M, Cates N, Langedijk JP, Meloen RH, Desrosiers RC, Burns DP, Bolognesi DP, et al.

Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1418-22.

39.

The ability of certain SIV vaccines to provoke reactions against normal cells.

Langlois AJ, Weinhold KJ, Matthews TJ, Greenberg ML, Bolognesi DP.

Science. 1992 Jan 17;255(5042):292-3. No abstract available.

PMID:
1549775
40.

Development of a vaccine for the prevention of AIDS, a critical appraisal.

Karzon DT, Bolognesi DP, Koff WC.

Vaccine. 1992;10(14):1039-52. Review.

PMID:
1281948
41.

Perspectives on the development of anti-HIV vaccines.

Bolognesi DP.

Curr Opin Biotechnol. 1991 Dec;2(6):893-6. Review.

PMID:
1367965
42.

Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: further clarifications.

LaRosa GJ, Weinhold K, Profy AT, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P, Bolognesi DP, Matthews TJ, Emini EA, et al.

Science. 1991 Sep 6;253(5024):1146. No abstract available.

PMID:
1887238
43.

The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-1) infected individuals.

Stine KC, Tyler DS, Stanley SD, Bartlett JA, Bolognesi DP, Weinhold KJ.

Cell Immunol. 1991 Aug;136(1):165-72.

PMID:
1905587
44.

In vitro assays for detecting neutralizing and fusion-inhibiting antibodies to SIVMAC251.

Langlois AJ, Weinhold KJ, Matthews TJ, Bolognesi DP.

AIDS Res Hum Retroviruses. 1991 Aug;7(8):713-20.

PMID:
1718347
45.

Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages.

Shadduck PP, Weinberg JB, Haney AF, Bartlett JA, Langlois AJ, Bolognesi DP, Matthews TJ.

J Virol. 1991 Aug;65(8):4309-16.

46.

AIDS vaccines: progress and unmet challenges.

Bolognesi DP.

Ann Intern Med. 1991 Jan 15;114(2):161-2. No abstract available.

PMID:
1984396
47.

HIV vaccine development: perspective.

Bolognesi DP.

Biotechnol Ther. 1991;2(1-2):205-11. No abstract available.

PMID:
1845122
48.

Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

Javaherian K, Langlois AJ, LaRosa GJ, Profy AT, Bolognesi DP, Herlihy WC, Putney SD, Matthews TJ.

Science. 1990 Dec 14;250(4987):1590-3. Erratum in: Science 1991 Jan 4;251(4989):13.

PMID:
1703322
49.

Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies.

Tyler DS, Stanley SD, Zolla-Pazner S, Gorny MK, Shadduck PP, Langlois AJ, Matthews TJ, Bolognesi DP, Palker TJ, Weinhold KJ.

J Immunol. 1990 Nov 15;145(10):3276-82.

PMID:
1700004
50.

Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys.

Hart MK, Palker TJ, Matthews TJ, Langlois AJ, Lerche NW, Martin ME, Scearce RM, McDanal C, Bolognesi DP, Haynes BF.

J Immunol. 1990 Oct 15;145(8):2677-85.

PMID:
1698859

Supplemental Content

Loading ...
Support Center